Question 1

What is Abecma?

Accepted Answer

Abecma is a chimeric antigen receptor (CAR) T-cell therapy, which is a type of treatment that uses a patient's own white blood cells to target cancer. It is a genetically modified autologous immunotherapy designed to help the immune system recognize and destroy cancer cells.

The treatment works by targeting a specific protein known as B-cell maturation antigen (BCMA). By focusing on this protein, the modified immune cells are able to identify and bind to the cancer cells to help eliminate them.

Question 2

What is Abecma used for?

Accepted Answer

Abecma is used to treat multiple myeloma .

Question 3

How does Abecma work?

Accepted Answer

Personalized Immunotherapy

Abecma is a type of treatment known as chimeric antigen receptor (CAR) T-cell therapy. It is a personalized medicine made from a patient's own white blood cells, specifically T cells, which are responsible for fighting infections and other diseases.

Targeting Multiple Myeloma

The treatment works by targeting a specific protein called B-cell maturation antigen (BCMA). This protein is found on the surface of both healthy and cancerous plasma cells, but it is especially prevalent in patients with multiple myeloma.

The process of creating and using Abecma involves several steps:

Collection: T cells are removed from the patient's blood through a process called leukapheresis.

Modification: In a laboratory, a new gene is added to these T cells. This gene gives the cells the ability to produce CAR proteins on their surface.

Recognition: These CAR proteins act like a navigation system, allowing the T cells to identify and latch onto the BCMA protein on cancer cells.

Elimination: After the modified cells are infused back into the patient, they seek out the cancer cells. When they connect with the BCMA protein, the T cells are activated to kill the cancer cells and begin to multiply within the body to continue the attack.

Question 4

What are the active ingredients in Abecma?

Accepted Answer

The active ingredient in Abecma is idecabtagene vicleucel .

Question 5

What are the side effects of Abecma?

Accepted Answer

Common side effects of Abecma may include:

fever

fatigue

nausea

and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Abecma?

Accepted Answer

Abecma belongs to the CAR T-cell therapy drug class.

Question 7

What is the dosage of Abecma and how do I take it?

Accepted Answer

Treatment Process

Receiving this medication involves several steps over a period of weeks. First, your white blood cells are collected through a process called leukapheresis. These cells are sent to a laboratory to be modified into the final treatment.

Before the Infusion

A few days before the treatment is administered, you will receive chemotherapy for three days. This helps prepare your body to receive the modified cells. Shortly before the infusion begins, you will also be given other medications, such as acetaminophen and an antihistamine, to help reduce the risk of a reaction during the procedure.

How the Medication is Given

The treatment is given as a one-time dose through an intravenous (IV) infusion into a vein. The procedure is performed by trained healthcare providers at a specialized facility that is certified to administer this type of therapy.

Monitoring

Because this treatment can cause serious reactions, you will be closely monitored during the infusion and for several weeks afterward. You may need to stay near the treatment center for a specific period following the procedure to ensure medical help is available if needed.

Question 8

Is Abecma safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known whether Abecma can cause harm to an unborn baby. There are no clinical trials or studies involving pregnant women, and animal reproduction studies have not been conducted for this medication. Because the risks to a developing fetus are unknown, healthcare providers typically require a pregnancy test for individuals of childbearing potential before beginning the treatment process.

Breastfeeding

There is no data regarding the presence of Abecma in human breast milk, its effects on a breastfed infant, or its impact on milk production. Because the potential for adverse reactions in a nursing child is unknown, it is important to discuss the risks and benefits of breastfeeding with a healthcare provider before starting treatment.

Question 9

What forms and strengths does Abecma come in?

Accepted Answer

Abecma is an autologous (patient-specific) cell suspension. This means the medication is custom-made for each individual using their own white blood cells, which are collected and genetically modified in a laboratory before being returned to the patient.

It is administered as a single-dose intravenous infusion by a healthcare professional in a clinical setting.

This medication is supplied in one or more infusion bags. Each bag contains a frozen suspension of genetically modified T cells. Because the treatment is manufactured specifically for each patient, the total volume and the number of bags used for the infusion can vary.

Form: Intravenous infusion (suspension).

Dosing: Single-dose treatment based on the number of modified cells.

Question 10

What is the FDA approval status of Abecma?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel) for the treatment of adults with relapsed or refractory multiple myeloma. It is specifically indicated for patients who have already received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Boxed Warning

Abecma carries a Boxed Warning, the FDA’s most serious type of warning, due to the risk of severe and potentially life-threatening side effects, including:

Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever and organ dysfunction.

Neurologic Toxicities: Also known as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which can cause confusion, seizures, or loss of consciousness.

Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS): A severe immune system overreaction.

Prolonged Cytopenia: Significantly low blood cell counts that last for several weeks after the infusion.

Risk Evaluation and Mitigation Strategy (REMS)

Because of these serious risks, the FDA requires a restricted program called the Abecma REMS. This program ensures that the therapy is only dispensed by certified healthcare facilities that are trained to recognize and manage severe side effects. Patients must be monitored daily for at least seven days following the infusion at the certified facility and must stay near the facility for at least four weeks.

Safety Communications

The FDA has issued communications regarding the risk of developing new blood cancers (T-cell malignancies) after treatment with CAR T-cell therapies like Abecma. While the FDA has determined that the overall benefits of these treatments outweigh the risks for their approved uses, the agency requires lifelong monitoring for new cancers in patients who receive these therapies.

Question 11

What should I know about Abecma and cost?

Accepted Answer

Factors Influencing Cost

The cost of Abecma can vary significantly based on several factors. Because it is a personalized CAR-T cell therapy, the process involves collecting a patient's own immune cells, modifying them in a laboratory, and infusing them back into the patient. This complex process requires specialized medical facilities and highly trained staff.

Additional costs often associated with Abecma treatment include:

Pre-treatment procedures: This includes chemotherapy (lymphodepletion) given before the infusion to prepare the body for the modified cells.

Hospitalization: Patients are typically required to stay in or near a certified treatment center for several weeks to monitor for serious side effects like cytokine release syndrome (CRS).

Long-term monitoring: Frequent follow-up appointments are necessary for several months to check for delayed reactions or complications.

Insurance and Financial Assistance

Most private insurance plans, as well as Medicare and Medicaid, may cover Abecma if specific medical criteria are met. However, insurance companies usually require prior authorization before the treatment process can begin.

The manufacturer may offer support programs to help patients navigate insurance coverage or provide financial assistance for those who qualify. Because Abecma is only available through a restricted program at specialized centers, patients and caregivers should speak with the financial counselor at their authorized treatment center. These counselors can help explore available options, including assistance with travel and lodging expenses if the treatment center is far from the patient's home.

Abecma

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?